Hims vs Ro for Weight Loss: Which Is Worth It in 2026?

Hims and Ro are two of the most-searched GLP-1 telehealth providers, and for good reason: both are large, well-funded platforms with national reach and polished apps. But they've taken different paths. Hims built its GLP-1 program around a Novo Nordisk partnership and is now focused on brand-name Wegovy as its primary offering. Ro built theirs around insurance coordination, helping patients navigate prior authorization for brand-name medications like Wegovy and Zepbound. The bottom line: if you have insurance you want to use, Ro is the stronger pick. If you're paying out of pocket and want brand-name Wegovy, Hims is competitive. Here's the full breakdown.

Quick comparison

	Hims	Ro
Price (as of April 2026)	From $199/mo (injectable Wegovy) + $149/mo membership	$145/mo membership + medication (total varies by medication type)
Medication options	Brand-name Wegovy (injectable and pill)	Wegovy (pen, pill, or vial), Zepbound, compounded semaglutide (select states)
Insurance support	No prior auth assistance	Yes: active insurance coordination included
Support level	Async messaging with care team	Educational weight-loss curriculum + care messaging
Availability	All 50 states	All 50 states
Best for	Out-of-pocket patients wanting brand-name or oral options	Insured patients seeking brand-name coverage help

Hims for weight loss

Hims entered the GLP-1 space through a partnership with Novo Nordisk, the manufacturer of Wegovy and Ozempic. That relationship gives Hims direct access to brand-name semaglutide products. As of April 2026, Hims offers brand-name Wegovy in injectable and pill formats as its primary GLP-1 offering.

Hims discontinued oral compounded semaglutide in Q1 2026 following FDA and Novo Nordisk legal pressure. The platform is now focused on FDA-approved brand-name options. Injectable Wegovy starts at $199/month for the medication; the Wegovy pill is also available at a lower starting price. All plans require a separate $149/month membership fee on top of medication cost.

Hims discontinued compounded semaglutide as a primary offering after the FDA declared the semaglutide shortage resolved in early 2025 (FDA drug shortages). The platform is now focused on FDA-approved options, which represents a meaningful shift in its position.

The support model is app-based and asynchronous. You can message your care team, but there are no scheduled coaching calls or behavioral curriculum. For patients who want to handle their own routine and just need a prescription and medication, that's fine. For patients who want more structure, Hims may feel light.

One genuine advantage: Hims is available in all 50 states, and the app is well-reviewed for usability.

Hims is best for: Patients paying out of pocket who want brand-name Wegovy and prefer a low-friction app experience.

Ro for weight loss

Ro's program is built around one specific problem: getting insurance to pay for brand-name GLP-1 medications. Prior authorization for Wegovy or Zepbound is notoriously difficult. Insurers frequently deny on the first submission, and the appeals process requires clinical documentation that most patients don't know how to assemble. Ro includes insurance coordination as part of its program, meaning their care team actively helps with prior auth submissions and appeals.

Ro's medication lineup is broader than Hims: Wegovy (available as a pen, pill, or cash-pay vial), Zepbound (tirzepatide), and compounded semaglutide in select states as a fallback option. The compounded semaglutide offered by Ro is not FDA-approved as a finished product, and availability varies by state and clinical eligibility.

Pricing runs $145/month membership plus medication (total varies by medication type, per Ro website, April 2026), which includes a $145/month membership plus medication. That's higher than most compounded alternatives, but the insurance coordination could make the total cost far lower if you have coverage. A successful prior auth could bring your medication cost to a copay of $25–$50/month on some plans.

Ro also includes an educational weight-loss curriculum alongside the medical program. It's not intensive coaching, but it's more structured than what Hims offers.

Ro is best for: Patients with employer insurance or marketplace plans who want real help getting brand-name coverage approved. Also a good fit if you want tirzepatide (Zepbound) options.

Where they differ most

Insurance handling is the clearest dividing line. Hims does not help with prior authorization. Their model assumes you're paying out of pocket. Ro's entire value proposition for insured patients is the prior auth coordination. That's what justifies their higher membership price. If you have insurance, this difference matters more than any other factor.

Medication sourcing philosophy is different. Hims went all-in on the Novo Nordisk partnership and pulled back from compounded offerings after the shortage resolution. Ro still carries compounded semaglutide in select states, which gives it more flexibility for patients who need a lower cash-pay option. But that flexibility comes with the regulatory caveat: compounded products are not FDA-approved as finished products.

The delivery format options differ. Both Hims and Ro offer Wegovy in injectable and pill formats. Ro additionally offers Wegovy in vial format and carries Zepbound (tirzepatide), which Hims does not. For patients who specifically want tirzepatide, Ro is the clear choice.

Support depth is similar, but Ro has a slight edge. Neither platform offers a full behavioral coaching program. That's what Found or Noom Med are designed for. But Ro's educational curriculum is more structured than Hims's async messaging model, which is closer to a simple prescription service.

The verdict

If you have insurance: Go with Ro. The prior authorization support is the feature that could save you hundreds of dollars per month. Even if your first submission is denied, Ro's team can help you appeal, something Hims simply doesn't offer. Ro's $145/month membership is separate from medication cost, so your total depends on medication type — but a successful prior auth could bring your medication cost down dramatically.

If you're paying out of pocket and want brand-name semaglutide: Hims is competitive. The injectable Wegovy program runs $348/month (medication + membership) and the Wegovy pill is available at a lower total. The lack of coaching won't matter to patients who just want a prescription and medication delivered reliably.

If you're paying out of pocket and open to compounded options: Neither Hims nor Ro is the best fit. Henry Meds starts at $149/month all-inclusive for compounded semaglutide, and TrimRx offers compounded semaglutide from $179/month all-inclusive. Both skip the separate membership fee structure. Compounded semaglutide contains the same active ingredient as brand-name versions but is not FDA-approved as a finished product.

If you're still unsure which program fits your situation, the quiz below takes about 90 seconds and factors in your insurance status, budget, and medication preferences.

Before choosing any GLP-1 program, consult your healthcare provider to confirm you're an appropriate candidate for semaglutide or tirzepatide treatment.

GLP-1 medications require a prescription from a licensed healthcare provider. This article is for informational purposes only and does not constitute medical advice. Compounded medications mentioned in this article are not FDA-approved as finished products. Always consult your healthcare provider before starting any medication.